Artificial intelligence (AI) has huge potential in bioprocessing. Its ability to model process data in real-time and feed this information into automated control systems is attractive to efficiency-focused drug companies.
According to a recent report, biopharma companies are warming to AI because of the prospect of lower costs and shorter timelines. Similarly, a report by Deloitte suggested, “AI technologies are poised to impact these [biomanufacturing] processes through real-time data processing and decision making that can make supply chains truly data-driven.
